Drug development describes the process of developing a new drug that effectively targets a specific weakness in a cell. This process involves specific pre-clinical development and testing, followed by ...

AI is increasingly used to accelerate and improve drug discovery and development. AI tools, like AlphaFold and autonomous labs, help identify targets and process massive datasets. Regulatory standards ...

Continuous process improvement can benefit all aspects of life — from personal New Year’s resolutions to complex drug development. In a world where two-thirds of planned improvement initiatives fail, ...

The Food and Drug Administration (FDA) development and approval process for drugs and medical devices involves multiple phases that ensure the safety and effectiveness of products before and after ...

The Food and Drug Administration is launching a pilot program intended to speed up the process of bringing new drug ...

Designing an efficient platform is crucial for any industrial process. This design process is known as process development, and it has become increasingly important in the pharmaceutical industry at ...

The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors and the general public. Researchers have applied ...

It is crucial to understand the drug development process and the many milestones and tasks that are essential to a comprehensive development plan to guarantee scientific and commercial success. While ...

Generative AI based on Large Language Models (LLMs), the technology behind popular tools like ChatGPT and Google Gemini, is revolutionizing various industries, including the world of drug discovery.

Drug discovery has traditionally been slow and expensive, often taking decades and costing manufacturers billions. Traditional methods, while advancing, are hitting limits in tackling the complexities ...

Some drugs may seem like they were named by throwing darts at the alphabet – but the process of drug naming is actually very intentional. In an interview with Fox News Digital, Dr. Dave Latshaw, CEO ...

Detailed analyses of ligand choice, linkage vector and linker length enabled the development of bitopic inhibitors of ABL1 and EGFR kinases, including an ABL1 inhibitor with enhanced activity against ...